Summit Therapeutics Inc. is a biopharmaceutical oncology company with a mission focused on improving quality of life, increasing potential duration of life, and resolving serious unmet medical needs. At Summit, we believe in building a team of world class professionals who are passionate about this mission, and it is our people who drive this mission to reality. Summit’s core values include integrity, passion for excellence, purposeful urgency, collaboration, and our commitment to people. Our employees are truly the heart and soul of our culture, and they are invaluable in shaping our journey toward excellence. Summit’s team is inspired to touch and help change lives through Summit’s clinical studies in the field of oncology. Summit has multiple global Phase 3 clinical studies, including:
Non-small Cell Lung Cancer (NSCLC)
HARMONi: Phase 3 clinical study which was intended to evaluate ivonescimab combined with chemotherapy compared to placebo plus chemotherapy in patients with EGFR-mutated, locally advanced or metastatic non-squamous NSCLC who were previously treated with a 3rd generation EGFR TKI. - HARMONi-3: Phase 3 clinical study which is intended to evaluate ivonescimab combined with chemotherapy compared to pembrolizumab combined with chemotherapy in patients with first-line metastatic NSCLC. - HARMONi-7: Phase 3 clinical study which is intended to evaluate ivonescimab monotherapy compared to pembrolizumab monotherapy in patients with first-line metastatic NSCLC.
Colorectal Cancer (CRC)
HARMONi-GI3: Phase 3 clinical study intended to evaluate ivonescimab in combination with chemotherapy compared with bevacizumab plus chemotherapy. Ivonescimab is an investigational therapy not presently approved by any regulatory authority other than China’s National Medical Products Administration (NMPA). Summit is headquartered in Miami, Florida, and has additional offices in California, New Jersey, the UK, and Ireland.
Overview of Role:
Reporting into the Vice President of Market Access, the Executive Director, US Market Access Strategy is responsible for developing and leading the US value strategy for Ivonescimab’s launch indications. This position will lead the development and execution of market access and payer marketing strategies in collaboration with other functions within the Market Access Organization and across the broader organization. Role and Responsibilities:
Lead the development of the US Market Access strategy to maximize the value of Ivonescimab while ensuring widespread patient access
Design and implement value communications materials for use within the market
Work effectively across the matrix organization partnering with HEOR, Pricing, Medical Affairs, Commercialization, Legal and other stakeholders. - Develop strategies, tactics, and promotional tools for the Payer Strategic Account and Key Provider Account field teams to use with healthcare decision makers based on the product value proposition and scientific platform, with input from Marketing and Medical Affairs teams
Collaborate in the development of pricing and contracting strategy, HEOR evidence generation plan, patient support programs, payer marketing and account management tactics
Lead regular discussions with internal and external partners to ensure coordinated approaches to coverage and reimbursement issues
Work with key stakeholders including Medical Affairs, Regulatory, Legal, Finance, Brand, CMC, Marketing, Sales, and Commercial Operations to ensure reimbursement issues are well understood and that solutions are developed and executed consistently and compliantly
Lead the overall Market Access organization financial budget and projections
Provide market access support for in-licensing and out-licensing business development initiatives as required
Collaborate with legal, regulatory, and compliance stakeholders to ensure compliant development and execution of market access initiatives
All other duties as assigned
Experience, Education and Specialized Knowledge and Skills:
BS/BA degree required, advanced degree a plus
A minimum of 12+ years of Market Access experience
Oncology, especially NSCLS (Non-Small Cell Lung Cancer) experience required / commercial launch experience required (2+ successful launches), solid tumor in addition to NSCLC experience required
Strong understanding of payer value drivers within oncology. - Demonstrated expertise and a proven track record in US Market Access with established relationships at leading national and regional payers / IDNs
Demonstrated ability to leverage research, scenario analyses and payer & pricing insights to generate global market access strategies that maximize product differentiation
Ability to identify new ways of articulating and visualizing market access strategies to enhance communication and decision-making
Experience supporting the development of payer value creation strategies and plans that go beyond the clinical evidence (e.g., Integrated Care, Patient Support Programs), to ensure, optimize and sustain access and product uptake
Successful record of achieving and maintaining compliance with all applicable regulatory, legal, and operational rules
Must be able to travel to support business priorities
